Scynexis is broadening an existing agreement with pharmaceutical giant Roche to discover and develop compounds to treat central nervous system and metabolic diseases.
Under the agreement, Roche will use Medchem Factory technology and “Hit Explorer Operator System” software that have been developed by Scynexis. Terms of the agreement were not disclosed.
Scynexis will receive technical access fees and “other compensation,” the company said. In exchange, Roche retains rights to develop any products that might evolve from the compound discovery process.
Scynexis has developed technology related to high-speed chemical synthesis.
Scynexis: www.scynexis.com
